CYP3A genetics in drug metabolism

被引：87

作者：

Eichelbaum, M

Burk, O

机构：

[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-7000 Stuttgart, Germany

[2] Univ Tubingen, Div Clin Pharmacol, Tubingen, Germany

来源：

NATURE MEDICINE | 2001年 / 7卷 / 03期

关键词：

D O I：

10.1038/85417

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Most drugs are metabolized by CYP3A enzymes, and variations in expression levels of these enzymes are believed to determine whether patients will have a positive or adverse drug response. Little is known about the mechanisms that underlie inter-individual differences in CYP3A expression, but the mapping of human genome sequence variations will facilitate the search for answers.

引用

收藏

页码：285 / 287

页数：3

相关论文

共 14 条

[1] NATURES CHEMICALS AND SYNTHETIC CHEMICALS - COMPARATIVE TOXICOLOGY .3. [J].

AMES, BN ;

PROFET, M ;

GOLD, LS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (19) :7782-7786

[2] cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome p450 [J].

Domanski, TL ;

Finta, C ;

Halpert, JR ;

Zaphiropoulos, PG .

MOLECULAR PHARMACOLOGY, 2001, 59 (02) :386-392

[3] The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module [J].

Goodwin, B ;

Hodgson, E ;

Liddle, C .

MOLECULAR PHARMACOLOGY, 1999, 56 (06) :1329-1339

[4] Use of the nuclear receptor PXR to predict drug interactions [J].

Moore, JT ;

Kliewer, SA .

TOXICOLOGY, 2000, 153 (1-3) :1-10

[5] Cytochrome P450 and the individuality of species [J].

Nelson, DR .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1999, 369 (01) :1-10

[6] Evaluation of the genetic component of variability in CYP3A4 activity:: a repeated drug administration method [J].

Özdemir, V ;

Kalow, W ;

Tang, BK ;

Paterson, AD ;

Walker, SE ;

Endrenyi, L ;

Kashuba, ADM .

PHARMACOGENETICS, 2000, 10 (05) :373-388

[7] Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors [J].

Rendic, S ;

DiCarlo, FJ .

DRUG METABOLISM REVIEWS, 1997, 29 (1-2) :413-580

[8] A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms [J].

Sachidanandam, R ;

Weissman, D ;

Schmidt, SC ;

Kakol, JM ;

Stein, LD ;

Marth, G ;

Sherry, S ;

Mullikin, JC ;

Mortimore, BJ ;

Willey, DL ;

Hunt, SE ;

Cole, CG ;

Coggill, PC ;

Rice, CM ;

Ning, ZM ;

Rogers, J ;

Bentley, DR ;

Kwok, PY ;

Mardis, ER ;

Yeh, RT ;

Schultz, B ;

Cook, L ;

Davenport, R ;

Dante, M ;

Fulton, L ;

Hillier, L ;

Waterston, RH ;

McPherson, JD ;

Gilman, B ;

Schaffner, S ;

Van Etten, WJ ;

Reich, D ;

Higgins, J ;

Daly, MJ ;

Blumenstiel, B ;

Baldwin, J ;

Stange-Thomann, NS ;

Zody, MC ;

Linton, L ;

Lander, ES ;

Altshuler, D .

NATURE, 2001, 409 (6822) :928-933

[9] CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12:: Evidence for an allelic variant with altered catalytic activity [J].

Sata, F ;

Sapone, A ;

Elizondo, G ;

Stocker, P ;

Miller, VP ;

Zheng, W ;

Raunio, H ;

Crespi, CL ;

Gonzalez, FJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (01) :48-56

[10]

SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414